Refractory Chronic Lymphocytic Leukemia

Oncology·MeSH: Lymphoma, B-Cell, Marginal Zone

Prevalence

20.0 / 100K

Incidence

4.7 / 100K/yr

10 drugs in development·6 companies·8 clinical trials

Drug Pipeline by Phase

Phase 3(2)

Drug	Company
alxn2075	ALEXION PHARMACEUTICALS, INC. (ALXN)
Sonrotoclax	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 2(4)

Drug	Company
ALLO-501A	Allogene Therapeutics, Inc. (ALLO)
ALLO-647	Allogene Therapeutics, Inc. (ALLO)
Pirtobrutinib	Filana Therapeutics Inc. (FLNA)
Pirtobrutinib	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 1(4)

Drug	Company
epcoritamab	Genmab A/S (GMAB)
Epcoritamab	Filana Therapeutics Inc. (FLNA)
Epcoritamab	ENANTA PHARMACEUTICALS INC (ENTA)
Epcoritamab	ELI LILLY & Co (LLY)

BioSniper tracks 10 drugs in development for Refractory Chronic Lymphocytic Leukemia across 6 companies.

There are 8 clinical trials targeting Refractory Chronic Lymphocytic Leukemia tracked by BioSniper.

The estimated prevalence of Refractory Chronic Lymphocytic Leukemia is approximately 20.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.